TRXB TRex Bio, Inc. Common stock
14.00USDMkt Cap: 384.24M $P/E: —Today
TRex Bio, Inc. operates as a clinical-stage biopharmaceutical company that engages in discovery and development of immunoregulatory medicines. It develops medicines that helps restore immune balance and promote tissue re…
Industry Peers
Biotechnology$129.20BUSDP/E 29.7
$89.83BUSD
$76.86BUSDP/E 18.5
$51.88BUSDP/E 31.4
$49.79BUSDP/E 32.4
$42.17BUSDP/E 18.0
$40.67BUSD
$40.33BUSDP/E 63.4
$32.90BUSDP/E 30.3
$31.13BUSDP/E 39.2
$25.60BUSD
$24.36BUSD
$22.86BUSDP/E 14.4
$22.79BUSDP/E 29.2
$21.90BUSDP/E 30.2
$21.97BUSD
$15.08BUSDP/E 17.6
$14.83BUSDP/E 18.9
$14.18BUSDP/E 15.0
$14.03BUSD
Key Statistics
Company
Market Cap384.24M USD
Enterprise Value189.76M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-46.39M USD
Revenue/Share—
Last Price14.00 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees60
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-3.84
EV/Revenue—
P/S—
P/B—
EPS (TTM)—
EPS (Forward)—
52W Range
13.5025% of range15.50
52W High15.50 USD
52W Low13.50 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE—
ROA—
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-46.25M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-90.66M USD
Net Debt/EBITDA1.83
Balance Sheet
Debt/Equity0.23
Current Ratio12.18
Quick Ratio11.87
Book Value/Sh—
Cash/Share19.04 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.27.45M
Float4.69M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta—
S&P 52W Chg18.51%
Avg Vol (30d)1.26M
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—